GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity.
The role of gap junctional intercellular communication (GJIC) in bystander killing with herpes simplex virus thymidine kinase (HSV-TK) and ganciclovir (GCV) was evaluated in U251 cells expressing a dominant-negative connexin 43 cDNA (DN14), and in HeLa cells, reportedly devoid of connexin protein. These cell lines both exhibited 0% GJIC when assayed by Lucifer Yellow fluorescent dye microinjection. Bystander cytotoxicity was still apparent in 50:50 cocultures of DN14 and HSV-TK-expressing U251 cells, but not in 50:50 cocultures of HeLa cells. However, the sensitivity of HeLa HSV-TK-expressing cells to GCV decreased nearly 100-fold (IC90=109 microM) when cocultured with bystander cells compared to results in 100% cultures of HSV-TK-expressing cells (IC90=1.2 microM). A more sensitive flow cytometry technique to measure GJIC over 24 h revealed that the DN14 and HeLa cells exhibited detectable levels of communication (29 and 23%, respectively). Transfer of phosphorylated GCV to HeLa bystander cells occurred within 4 h after drug addition, and GCV triphosphate (GCVTP) accumulated to 213+/-84 pmol/10(6) cells after 24 h. In addition, GCVTP levels were decreased in HSV-TK-expressing cells in coculture (867+/-33 pmol/10(6) cells) compared to 100% cultures of HSV-TK-expressing cells (1773+/-188 pmol/10(6) cells). The half-life of GCVTP in the HSV-TK-expressing cells was approximately four times that measured in the bystander cells (12.3 and 3.1 h, respectively). These data suggest that the lack of bystander cytotoxicity in HeLa cocultures is due to low transfer of phosphorylated GCV and a rapid half-life of GCVTP in the bystander cells. Thus, GCV phosphate transfer to non-HSV-TK-expressing bystander cells may mediate either bystander cell killing or sparing of HSV-TK-positive cells, depending upon the cell specific drug metabolism.
Gentry
B G
BG
Department of Pharmacology, University of Michigan Medical Center, Ann Arbor, Michigan 48109-0504, USA.
Im
M
M
Boucher
P D
PD
Ruch
R J
RJ
Shewach
D S
DS
D000998:Antiviral Agents / Q000493:pharmacokinetics*; D001692:Biological Transport; D002450:Cell Communication; D045744:Cell Line, Tumor; D002470:Cell Survival; D018920:Coculture Techniques; D004396:Coloring Agents; D018031:Connexin 43 / Q000032:analysis / Q000235:genetics; D018076:DNA, Complementary / Q000378:metabolism; D005260:Female; D005434:Flow Cytometry; D015774:Ganciclovir / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D017629:Gap Junctions / Q000378:metabolism*; D015316:Genetic Therapy / Q000379:methods*; D006207:Half-Life; D006367:HeLa Cells; D018259:Herpesvirus 1, Human / Q000201:enzymology; D006801:Humans; D007546:Isoquinolines; D008856:Microscopy, Fluorescence; D013937:Thymidine Kinase / Q000378:metabolism
D000998:Antiviral Agents; D004396:Coloring Agents; D018031:Connexin 43; D018076:DNA, Complementary; D007546:Isoquinolines; C092309:ganciclovir triphosphate; C017475:lucifer yellow; D013937:Thymidine Kinase; D015774:Ganciclovir